Astazi avocatii companiilor Apple si Samsung au renuntat astazi la o parte dintre pretentiile pe care le aveau intr-un proces pentru a expedia actiunea si a ajunge in fata unui judecator in vara acestui an. Fiecare companie a renuntat la aproximativ jumatate dintre pretentiile pe care le avea in respectivul proces, insa chiar si asa nu se stie daca toul va merge asa cum si-au dorit avocatii. Apple sustine ca Samsung nu ar fi devenit cel mai mare vanzator de smartphone-uri daca nu ar fi copiat iPhone-ul si sustine ca daunele cauzate de compania coreeana se ridica la cateva miliarde de dolari.
While the parties have been readying the case for trial Samsung has vaulted into first place in worldwide sales of smartphones, with massive sales of its copycat products. Samsung’s infringement of Apple’s intellectual property has already resulted in damages that reach billions of dollars. […] It is critical to Apple to start trial on July 30, to put an end to Samsung’s continuing infringement.
Samsung pe de alta parte spune ca Apple nu este capabila sa o concureze pe piata si ca pana acum nu a prezentat vreo dovada clara a faptului ca iDevice-urile au fost in vreun fel copiate. Presupun ca avocatii din SUA au memoria scurta si au uitat ca Apple a reusit sa blocheze vanzarea unor terminale Samsung in Germania si Australia din cauza incalcarii brevetelor de inventie. Desi avocatii celor doua companii continua procesele deschise in instantele de pe glob, Tim Cook si CEO-ul Samsung se vor intalni pentru a ajunge la un acord si a opri aceste dispute, insa ramane de vazut daca vor si reusi.
Apple has only been able to muster utility patents covering extremely minor user interface features, and design patents and trade dresses that offer far narrower protection than Apple urges. There’s a lot of diplomacy and politics involved here. But even between two companies from the same country, it would be virtually impossible to get a court to determine, ahead of summary judgment and a trial, that one party has a fundamentally better case, no matter how strong the indications may be.
